IRX-2, Cyclophosphamide, and Nivolumab in Treating Patients With Recurrent or Metastatic and Refractory Liver Cancer
City of Hope Medical Center
City of Hope Medical Center
Teclison Ltd.
University of Pittsburgh
National Cancer Institute (NCI)
TaiRx, Inc.
7 Hills Pharma, LLC
Parabilis Medicines, Inc.
NRG Oncology
Bristol-Myers Squibb
University of Hawaii
National Cancer Institute (NCI)
China Medical University Hospital
Shanghai Henlius Biotech
Exelixis
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
Hefei TG ImmunoPharma Co., Ltd.
ImmunityBio, Inc.
Bristol-Myers Squibb
Bristol-Myers Squibb
Bristol-Myers Squibb
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
University of Pittsburgh
Mayo Clinic
Bristol-Myers Squibb
TriSalus Life Sciences, Inc.
CatalYm GmbH
NYU Langone Health
Academic and Community Cancer Research United
National Cancer Centre, Singapore
Incyte Corporation
The First Hospital of Hebei Medical University
University of California, Irvine